« Return to News | Drug Sponsors

Valeant approaches Cephalon with buyout offer

Wednesday, March 30, 2011 01:55 PM

Valeant Pharmaceuticals International, based in Canada, has made an unsolicited bid to buy U.S.-based Cephalon, a biopharmaceutical company, for $5.7 billion.

Valeant is bidding $73.00 per share in cash, which represents a premium of approximately 29% over Cephalon's 30-day trading average. Valeant group says it prefers "a consensual process" and has made "several private approaches" but "has been disappointed by Cephalon's unwillingness to engage in discussions in a timely manner," according to PharmaTimes.

Valeant chief executive Michael Pearson said "We have taken a close look at Cephalon's business and believe we put forward a very compelling offer." He added that "we are also committed to trying to find additional value if we are allowed to conduct due diligence."

Pearson said "we intend to be disciplined on price" and "if our offer does not have the requisite support of Cephalon's stockholders, we will focus our attention on other opportunities to invest our capital." However, he indicated that the bid could be increased after due diligence.

Cephalon’s board says it will consider the unsolicited proposal. In a letter to Pearson, chief executive of Cephalon Kevin Buchi said "your timing was propitious, since my management team was meeting last week to commence our long range planning process."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.